Pathology: mBC - TNBC - L1 - all population; mBC - TNBC - L1 - PDL1 positive;
| mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | ||
| IMpassion-130 (all population), 2018 | IMpassion-130 (PDL1>1%), 2018 | ||
| atezolizumab plus nab-paclitaxel | 2 | T1 | T1 |
| Standard of Care (SoC) | 0 | T0 | T0 |